Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy

NCT05861986 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05861986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05861986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Recruiting
Start date
May 30, 2024
Completion date
March 31, 2029
Enrollment
28 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

muscular atrophy, spinal